Takeda Sues Mylan Over Generic Acid Reflux Drug

Law360, New York (August 29, 2013, 3:38 PM EDT) -- Takeda Pharmaceutical Co. Ltd. on Wednesday sued rival Mylan Inc. in California federal court, alleging that planned generic versions of acid reflux drug Dexilant infringe multiple patents.

According to Takeda, abbreviated new drug applications filed by generic-drug maker Mylan and its subsidiary Mylan Pharmaceuticals Inc., seeking U.S. Food and Drug Administration approval to make and sell generic dexlansoprazole capsules in 30 and 60 milligram dosage strengths, infringe U.S. Patent Numbers 6,462,058; 6,664,276; 6,939,971; 7,285,668; and 7,790,755.

Takeda also filed an action in the same court against...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.